Literature DB >> 24602564

Poly(ADP-ribose)polymerase (PARP) inhibitors: from bench to bedside.

R Plummer1.   

Abstract

Poly(ADP-ribose)polymerase (PARP) inhibitors are a novel class of anticancer agents that target the DNA damage response pathways. The enzyme target, PARP, plays a key role in signalling DNA single-strand breaks. Clinical development to date has focused on their potential role in combination with DNA-damaging chemotherapy, where efficacy has been limited by enhanced normal tissue toxicity, and as single agents in the context of synthetic lethality. This article reviews these data in the context of future development as radio-potentiating agents.
Copyright © 2014 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemo-potentiation; DNA damage response; poly(ADP-ribose)polymerase (PARP); radio-potentiation; synthetic lethality

Mesh：

Substances：

Year:  2014        PMID： 24602564     DOI： 10.1016/j.clon.2014.02.007

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


  6 in total

1.  Linking DNA polymerase theta structure and function in health and disease.

Authors:  Kelly Beagan; Mitch McVey
Journal:  Cell Mol Life Sci       Date:  2015-10-29       Impact factor: 9.261

2.  Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.

Authors:  Likun Li; Styliani Karanika; Guang Yang; Jiangxiang Wang; Sanghee Park; Bradley M Broom; Ganiraju C Manyam; Wenhui Wu; Yong Luo; Spyridon Basourakos; Jian H Song; Gary E Gallick; Theodoros Karantanos; Dimitrios Korentzelos; Abul Kalam Azad; Jeri Kim; Paul G Corn; Ana M Aparicio; Christopher J Logothetis; Patricia Troncoso; Timothy Heffernan; Carlo Toniatti; Hyun-Sung Lee; Ju-Seog Lee; Xuemei Zuo; Wenjun Chang; Jianhua Yin; Timothy C Thompson
Journal:  Sci Signal       Date:  2017-05-23       Impact factor: 8.192

Review 3.  Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.

Authors:  Geraldine OʼSullivan Coyne; Alice Chen; Shivaani Kummar
Journal:  Curr Opin Oncol       Date:  2015-11       Impact factor: 3.645

Review 4.  New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology.

Authors:  Anne Roulston; Gordon C Shore
Journal:  Mol Cell Oncol       Date:  2015-06-10

5.  Design, Synthesis, and Biological Evaluation of Novel PARP-1 Inhibitors Based on a 1H-Thieno[3,4-d] Imidazole-4-Carboxamide Scaffold.

Authors:  Lingxiao Wang; Feng Liu; Ning Jiang; Wenxia Zhou; Xinbo Zhou; Zhibing Zheng
Journal:  Molecules       Date:  2016-06-13       Impact factor: 4.411

6.  Induction of Poly(ADP-ribose) Polymerase in Mouse Bone Marrow Stromal Cells Exposed to 900 MHz Radiofrequency Fields: Preliminary Observations.

Authors:  Qina He; Yulong Sun; Lin Zong; Jian Tong; Yi Cao
Journal:  Biomed Res Int       Date:  2016-04-14       Impact factor: 3.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.